Mortality after infection with methicillin-resistant Staphylococcus aureus (MRSA) diagnosed in the community

BackgroundOutbreak reports suggest that community-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections can be life-threatening. We conducted a population based cohort study to assess the magnitude of mortality associated with MRSA infections diagnosed in the community.MethodsWe used the United Kingdom's General Practice Research Database (GPRD) to form a cohort of all patients with MRSA diagnosed in the community from 2001 through 2004 and up to ten patients without an MRSA diagnosis. The latter were frequency-matched with the MRSA patients on age, GPRD practice and diagnosis date. All patients were older than 18 years, had no hospitalization in the 2 years prior to cohort entry and medical history information of at least 2 years prior to cohort entry. The cohort was followed up for 1 year and all deaths and hospitalizations were identified. Hazard ratios of all-cause mortality were estimated using the Cox proportional hazards model adjusted for patient characteristics.ResultsThe cohort included 1439 patients diagnosed with MRSA and 14,090 patients with no MRSA diagnosis. Mean age at cohort entry was 70 years in both groups, while co-morbid conditions were more prevalent in the patients with MRSA. Within 1 year, 21.8% of MRSA patients died as compared with 5.0% of non-MRSA patients. The risk of death was increased in patients diagnosed with MRSA in the community (adjusted hazard ratio 4.1; 95% confidence interval: 3.5–4.7).ConclusionMRSA infections diagnosed in the community are associated with significant mortality in the year after diagnosis.

[1]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[2]  L. Abenhaim,et al.  The quality of information recorded on a UK database of primary care records: A study of hospitalizations due to hypoglycemia and other conditions , 1994 .

[3]  G. Tillotson,et al.  Methicillin-resistant Staphylococcus aureus (MRSA) in the community , 1995, The Lancet.

[4]  S Greenland,et al.  Basic methods for sensitivity analysis of biases. , 1996, International journal of epidemiology.

[5]  T. Walley,et al.  The UK General Practice Research Database , 1997, The Lancet.

[6]  S. Pocock,et al.  Impact of Missing Data Due to Selective Dropouts in Cohort Studies and Clinical Trials , 2002, Epidemiology.

[7]  O. Lyytikäinen,et al.  Changing epidemiology of methicillin-resistant Staphylococcus aureus in Finland. , 2004, The Journal of hospital infection.

[8]  Michal Abrahamowicz,et al.  Using generalized additive models to reduce residual confounding , 2004, Statistics in medicine.

[9]  M. Wallander,et al.  Predictors and prognosis of paroxysmal atrial fibrillation in general practice in the UK , 2005, BMC cardiovascular disorders.

[10]  R. Lynfield,et al.  Methicillin-resistant Staphylococcus aureus disease in three communities. , 2005, The New England journal of medicine.

[11]  B. Thiers Methicillin-Resistant Staphylococcus Aureus Disease in Three Communities , 2005 .

[12]  M. Kollef,et al.  Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. , 2005, Chest.

[13]  Mian Cai,et al.  Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  D. Talan,et al.  Methicillin-resistant Staphylococcus aureus in Community-acquired Skin Infections , 2005, Emerging infectious diseases.

[15]  William R Bishai,et al.  Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. , 2005, The Lancet. Infectious diseases.

[16]  Donald Morrison,et al.  Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone , 2005, The Lancet.

[17]  J. Boyce,et al.  Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat , 2006, The Lancet.

[18]  R. Hubbard,et al.  Is an internal comparison better than using national data when estimating mortality in longitudinal studies? , 2006, Journal of Epidemiology and Community Health.

[19]  M. Mulvey,et al.  Outbreak in Alberta of community-acquired (USA300) methicillin-resistant Staphylococcus aureus in people with a history of drug use, homelessness or incarceration , 2006, Canadian Medical Association Journal.

[20]  S. Suissa,et al.  Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy , 2006, Canadian Medical Association Journal.

[21]  H. Maltezou,et al.  Community-acquired methicillin-resistant Staphylococcus aureus infections. , 2006, International journal of antimicrobial agents.

[22]  Roberta B Carey,et al.  Methicillin-resistant S. aureus infections among patients in the emergency department. , 2006, The New England journal of medicine.

[23]  M. Turchi,et al.  Staphylococcus aureus bacteraemia: incidence, risk factors and predictors for death in a Brazilian teaching hospital. , 2006, The Journal of hospital infection.

[24]  Christine Klein,et al.  BMC Medicine , 2006 .

[25]  Tim E A Peto,et al.  Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study , 2006, BMJ : British Medical Journal.

[26]  S. Schneeweiss Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics , 2006, Pharmacoepidemiology and drug safety.

[27]  P. Gustafson,et al.  Bayesian sensitivity analysis for unmeasured confounding in observational studies , 2007, Statistics in medicine.

[28]  Erica E M Moodie,et al.  Demystifying Optimal Dynamic Treatment Regimes , 2007, Biometrics.

[29]  S. Suissa,et al.  Antimicrobial Drugs and Community-acquired Methicillin-Resistant Staphylococcus aureus, United Kingdom , 2007, Emerging infectious diseases.

[30]  Samy Suissa,et al.  Primer: administrative health databases in observational studies of drug effects—advantages and disadvantages , 2007, Nature Clinical Practice Rheumatology.

[31]  Wei-Jen Lin,et al.  Nasal carriage of a single clone of community-acquired methicillin-resistant Staphylococcus aureus among kindergarten attendees in northern Taiwan , 2007, BMC infectious diseases.

[32]  Samy Suissa,et al.  Immortal time bias in observational studies of drug effects , 2007, Pharmacoepidemiology and drug safety.

[33]  L. Miller,et al.  A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.